HotMasterAn innovative Hot Start/Cold Stop technology for better ,,, PCR* results
Conclus...Eppendorf HotMaster Taq DNA Polymerase offers several advantages over ... *This product is sold under licensing arrangements with... ... ...
Conclusions
Eppendorf HotMaster Taq DNA Polymerase offers several advantages over
other Hot Start DNA polymerases. First and foremost, HotMaster Taq both
reduces non-specific PCR products and increases specific yield to a greater
extent than the major Hot Start DNA polymerases on the market. This is
primarily due to the significant advantages of this kit such as Hot
Start/Cold Stop technology. In addition, no heat activation is required
with HotMaster, and target sizes of up to 5.0 kb can be efficiently and
reproducibly amplified. Furthermore, the Mg++ concentration is self-adjusting,
which makes it optimal for virtually all targets. Lastly, because of its
unique technology, HotMaster will not contaminate PCR reactions with unwanted
proteins as do the Hot Start DNA polymerases that employ antibodies to
achieve inhibition. Testing has also shown that HotMaster Taq can be used
in real time PCR applications (data not shown).
*This product is sold under licensing arrangements with F. Hoffmann-La
Roche Ltd., Roche Molecular Systems, Inc., and Applied Biosystems.
'"/>Source:
Page: All 1 2 3 4 5 6 7 Related biology technology :1.
Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
(Date:11/24/2009)... Health care employment grew by ...only one to show consistent growth during the U.S....ls remain in trouble, and health systems are comin...el, instead of just administrators. , ...are employment continued growing in October despit...
(Date:11/24/2009)...HANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxyan...(SFDA)hasapprovedthe,investigationalnewdrugapplica...ativeinsulinformulationtotreatdiabetes.ThisIND,app...study. , Diabetesisadisordercharacteristicofh...ofdiabetesoftenresultinseveremicro-and,macro-vascu...
(Date:11/24/2009)...SXVENTURE:HTL , TORONTO,Nov.24/PRNewswire-Fir...ttoCapitalInc.,aleadingproviderofadvancedlasersyst...yclinicmarkets,todayreportedoperationalandfinancia..., ,Q32009Highlights,-Revenuewas$1.46millioncompar....3percentcomparedwith66.1percentinQ3,2008,-Netloss...
(Date:11/24/2009)...OZEN,Italy,November24/PRNewswire/--HealthRoboticst...urewithagroupofselected,investors.Thisrecentlyform...thRoboticsCanada,Inc.andwillmarket,install,andsupp...hincludesthe,revolutionaryproductofferingsi.v.STAT...adaInc.willalsoprovideassistanceonan"asneeded,basi...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2...sia-FirstCall/ -- Genesis,Pharmaceuticals Enterpri... the,"Company"), a U.S. pharmaceutical company wit...c of China, today announced its financial results ...ed December 31, 2008. , , Second Quarter of Fis...million, up 24.1% from the corresponding quarter, ...
...tech Industry , , FT. LAUDERDALE, Fla., Feb. 17 ...full-service securities broker-dealer and investme... Newbridge BioVentures Division ("NBV"). NBV is de...or the biotech industry and related investment opp...ividual investors. , , We are pleased to announce...
...ences, Inc. (Nasdaq: HGSI ) today announced that...ase 3 clinical trial program to evaluate the effic...glutide) in the long-term treatment of type 2 diab... million milestone payment in the first quarter of.../prnh/20080416/HGSLOGO ) , , "We are delighted t...
Other Biology Technology:Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16Newbridge Securities Corporation Forms BioVentures Division 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4...r forum for health care executives to explore a my...aders. The 2008 Congress will include senior execu...argest employers, hospitals, health systems, healt... government. , One of the programs many highlight...re key health care advisors to Presidential hopefu...
...iversity have confirmed for the first time that a ...least the past 23 years and will likely remain the...fe in the area. , Steve DiMarco, associate profes...tudied dead zones in the Gulf of Mexico for more t...Texas coast extends from the Texas-Louisiana borde...
...omen use hormone replacement therapy (HRT) as a me... In a recent University of Missouri study, researc... synthetic progestin, could be a major factor in p...archers have compelling evidence that using an ant...tumors, or a small molecular drug, known as PRIMA,...
Other Biology News:5th Annual World Health Care Congress April 21-23, Washington, D.C. 2Researchers confirm dead zone off Texas coast since 1985 2MU researcher links hormone replacement therapy to breast cancer 2Sheep Anti-FLECAINIDE Polyclonal Antibody, Unconjugated from AbD Serotec
...or use in refrigerators, freezers, or liquid nitro...ks. Four vibrant colors allow for color coding to ... liquid nitrogen drainage or promote cool air circ...hich holds 81 tubes. Box dimensions: 13 x 13 x 5...
Rhesus Monkey IFN-Alpha from Cell Sciences
Rabbit Anti-HAX1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: